The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of disitamab vedotin in combination with RC148 versus albumin-bound paclitaxel ± toripalimab for patients with HR-negative HER2-low-expressing unresectable locally advanced or metastatic breast cancer: An open-label, randomized, controlled phase II study.
 
Jiayu Wang
No Relationships to Disclose
 
Quchang Ouyang
No Relationships to Disclose
 
Xiying Shao
No Relationships to Disclose
 
Wenbin Zhou
No Relationships to Disclose
 
Yongsheng Wang
No Relationships to Disclose
 
Weimin Xie
No Relationships to Disclose
 
Jingfen Wang
No Relationships to Disclose
 
Aimei Jiang
No Relationships to Disclose
 
Changwen Li
No Relationships to Disclose
 
Zerui Qu
Employment - RemeGen Co., Ltd.
 
Chenran Han
Employment - RemeGen Co., Ltd.
 
Bo Yang
Employment - RemeGen Co., Ltd.
 
Jianmin Fang
Stock and Other Ownership Interests - RemeGen Co., Ltd.
 
Binghe Xu
Consulting or Advisory Role - AstraZeneca; Novartis